



Clinical profi ling of patients with 
peripartum cardiomyopathy and its value 
for translational research
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INTRODUCTION                                                                
Peripartum cardiomyopathy (PPCM) is a distinct entity of dilated 
cardiomyopathy that occurs in women between 1 month antepartum 
and 5 months postdelivery.(1, 2) The low incidence of PPCM in the 
northern hemisphere (1:15 000) as compared to countries like Nigeria, 
Haiti and South Africa with an incidence between 1:100 to 1:1 000,(3-7) 
is one of the reasons why numerous previous studies on PPCM relied 
on case reports, small numbers of patients or a review of medical 
records. One option was even a survey among 15 000 members of the 
American College of Cardiology by mail(8) in an effort to obtain basic 
information that totaled 123 patients.(9) Only patients in Haiti were 
studied prospectively by the same group of doctors, but given the 
political situation, researchers were faced with practical and logistical 
diffi culties.   
Many reports on PPCM were written before the advent of 
echocardiography, an essential investigation into the diagnosis of PPCM. 
As a result, previous reports and studies most likely included a signifi cant 
percentage of patients with a non-PPCM cause of cardiac malfunction 
that clinically mimic heart failure. The criteria for PPCM were re-defi ned 
in 1997,(1) emphasizing the absence of other underlying cardiac 
conditions to help refi ne the diagnosis of human PPCM. This problem 
of inaccurate diagnosis is refl ected by the fact that select studies of 
human PPCM included a high percentage of patients with other cardiac 
conditions, e.g. a history of hypertension during pregnancy in 43% of 
patients.(9) Furthermore, ACE-inhibitors or β-blockers were not 
available during many of the early studies, impacting negatively on 
outcome. 
In view of the above, systematic data collection to study the aetiology 
and the potential pathogenic mechanisms of PPCM was deemed 
diffi cult. The high incidence of PPCM at a single tertiary centre in South 
Africa provided a unique opportunity to conduct a prospective study 
of the mechanism of the pathogenesis and clinical features of PPCM. 
This enabled us to perform a translational study and novel therapeutic 
approach to treat patients with a high risk for PPCM. Based on data 
obtained from an animal model of PPCM (mice with a cardiomyocyte-
specifi c knock-out of signal transducer and activator of transcription 
(STAT)3, alpha-MHC-cre+/o; stat3fl ox/fl ox: STAT3-KO)(10) we emphasized 
that a biologically active degradation product of the nursing hormone 
prolactin might be a major cause of the development of PPCM. 
Treatment with bromocriptine, a drug widely used to stop lactation in 
women, prevented PPCM completely in our mouse model. Interestingly, 
we discovered striking parallels between the prolactin based 
pathomechanism in STAT3-KO mice and patients with PPCM.(10) Based 
on these experimental fi ndings, a pilot trial with bromocriptine was 
started at our center, including 12 patients with a high risk for PPCM 
due to a PPCM in a previous pregnancy. 
In summary, this review points out the systematic data collection and 
analysis of 100 patients with PPCM. In addition, we made use of our 
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Postpartum cardiomyopathy (PPCM) is 
a disease of unknown etiology and exposes women to high 
risk of mortality after delivery despite optimal medical 
therapy. Experimental data suggested that enhanced 
oxidative stress promotes the proteolytical processing of 
the lactation hormone prolactin into a biologically active 
derivative, the 16kDa prolactin, which appears to be a 
major cause for PPCM. We observed increased oxLDL 
levels in a subset of these PPCM patients, indicative of 
oxidative stress, enhanced Cathepsin D activity and 
substantial levels of the cleaved 16kDa form of prolactin. 
We therefore propose that the excessive generation of 
16kDa prolactin mediates PPCM in humans and suggest 
that inhibition of prolactin release may represent a novel 
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genetic mouse model of PPCM to investigate potential underlying 
mechanisms, which may start and/or drive this disease and took a 
translational approach to investigate potential novel treatment strategies 
specifi cally addressing PPCM. 
CLINICAL PROFILE OF 100 PATIENTS WITH               
PERIPARTUM CARDIOMYOPATHY
Study design and patient enrolment
The protocol was approved by the Committee for Research on Human 
Subjects of the University of the Witwatersrand, Johannesburg, South 
Africa and complies with the Declaration of Helsinki. All patients and 
controls gave written informed consent before study entry. Clinical 
assessment, echocardiography, and blood analysis were done at baseline 
and after 6 months of standard therapy. Infl ammatory markers were 
measured at baseline only.  All patients received treatment with diuretics 
and the angiotensin-converting enzyme inhibitor accupril. Carvedilol 
was added after resolution of overt heart failure, and the dose was 
slowly titrated up to a target of 25 mg twice daily as long as SBP was 
≥ 100 mmHg or symptoms such as dizziness did not occur. Patients 
attended the cardiac clinic at least once a month for routine follow-ups. 
Inclusion criteria, exclusion criteria, measurement of tumour-necrosis 
factor (TNF)-alpha and Fas/APO-1 levels, assessment of New York 
Heart Association (NYHA) functional class, echocardiography and 
details of the statistical analysis are described elsewhere.(11) 
Clinical profi le of 100 study patients with PPCM
Seventy-seven out of the 100 patients completed the follow-up period 
of six months - 15 patients had died and eight had moved to remote 
areas and were not available for follow-up. The mean age was 31.6±6.6 
years and 23.2% had undergone caesarean section. The mean 
haemoglobin at time of presentation was 12.5±1.7 g/dl and mean 
body mass index (BMI) was 25.6±5.1. Patients were normotensive 
with a mean systolic blood pressure of 111.1±17.4 mmHg over 
70.4±13.5 mmHg diastolic and tachycardic (93.5±18.5 b.p.m.).  Although 
91% of the study patients were diagnosed as PPCM patients for the 
fi rst time, the remaining 9 PPCM patients had been diagnosed at a 
previous pregnancy. These nine patients had recovered their left 
ventricular (LV) function and experienced a subsequent episode of 
PPCM. None of the patients had identifi able causes for heart failure. 
There was no association between history of hypertension and 
eclampsia during pregnancy or use of tocolytic agents (9%). On 
presentation at the clinic (baseline), 26 patients were in NYHA FC II, 
49 in functional class (FC) III and 25 in FC IV. Left ventricular thrombi 
were detected on echocardiography in 16% of the patients. 
During the fi rst months after enrolment, patients received standard 
therapy for heart failure, which included furosemide [n = 96, median 
daily dose 160 mg (80–250)], accupril [n = 96, median daily dose 10 mg 
(10–20)], and carvedilol [n = 95, median daily dose 25 mg (6.25–50)]. 
Carvedilol was uptitrated as long as SBP was > 100 mmHg or symptoms 
such as dizziness did not occur. After six months of treatment, surviving 
patients presented with lower heart rate (p=0.001), higher systolic 
(p=0.018) but unchanged diastolic blood pressure (p=0.37). Left 
ventricular diastolic dimensions improved from 61.2±7.1 mm to 
55.6±8.9 mm (p<0.0001) and end-diastolic dimensions from 53.4±7.7 
mm to 43.7±10.3 mm (p<0.0001). Left ventricular ejection fraction 
(LVEF) improved from 26.2±8.2% to 42.9±13.6% (p<0.0001) as 
determined by echocardiography and from 23.9±8.1% to 43.1±15.1% 
as measured by multiple gated acquisition scan (MUGA) (<0.0001). 
However, normalization of LVEF (>50%) was only observed in 
18 (23%) of the patients. The median plasma level of C-reactive protein 
(CRP) for the 100 PPCM patients was 10.0 mg/L (range 1–90) with 
45% of patients having values of .10 mg/L (Table 1). Only ten patients 
had a C-reactive protein level of 3 mg/L. Baseline plasma levels of 
C-reactive protein correlated positively with LV end-diastolic (rs = 0.33, 
P = 0.0026) and end-systolic dimensions (rs = 0.35, P = 0.0012), 
whereas the correlation with LVEF (rs = 20.27, P = 0.015) was inverse 
(Figure 1). Plasma C-reactive protein levels also correlated inversely 
TABLE 1:  Baseline characteristics of study population (n=100)
C-reactive protein (mg/l) 10.8±13.2
Glucose (mmol/L) 4.8±1.1




FIGURE 1:  Correlation co-effi cients of total cholesterol and C-reactive protein vs. 
parameters of LV dimensions and function.(11)
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with levels of total cholesterol (rs = 20.29, P = 0.01). Baseline plasma 
levels of C-reactive protein, TNF-alpha, and Fas/Apo-1 were elevated in 
patients with PPCM when compared with 20 age, sex, body mass index, 
and parity comparable healthy volunteers (TNF-alpha 4.9±4.2 vs. 
1.4±1.3 pg/mL, Fas/Apo-1 6.3±4.1 vs. 0.84±0.2 U/L, C-reactive protein 
10.8±13.2 vs. 3.1±0.9 mg/L, P = 0.01). There was no correlation 
between baseline plasma levels of C-reactive protein, TNF-alpha, and 
Fas/Apo-1 among the PPCM patients. 
In the population studied, mortality remained high (15%). Signifi cant 
differences in the baseline data between deceased patients and 
survivors were seen in NYHA FC, values of systolic blood pressure 
(SBP), end-diastolic and end-systolic dimensions, LVEF, plasma aspartate 
aminotransferase (AST) and plasma levels of Fas/Apo-1 (Figure 2). 
Logistic regression analysis of NYHA FC, SBP, end-diastolic dimension 
(EDD), end-systolic dimension (ESD), EF, AST, and Fas/Apo-1 revealed 
that only the baseline plasma levels of Fas/Apo-1 (OR = 3.56, CI 95% 
= 1.35–9.42, p=0.01) and NYHA FC (OR = 2.67, CI 95% = 1.04–6.83, 
p=0.04) were independent predictors of death.
TRANSLATIONAL APPROACH FROM MOUSE TO 
(WO)MAN
A mouse model of PPCM
In studies by us and others it was shown that male mice with a 
cardiomyocyte-specifi c knock-out of STAT3, STAT3-KO spontaneously 
develop dilated cardiomyopathy with older age, associated with 
increased apoptosis of cardiomyocytes.(12, 13) We have demonstrated 
that an activated Fas/Fas ligand system promotes apoptosis of 
endothelial cells in the myocardium of STAT3-KO males.(13) Moreover, 
we noted that homozygotic STAT3-KO female mice and, to a lesser 
extent, heterozygotic (αMHC-cre+/o; stat3fl ox/+) female mice 
invariably develop PPCM, with a phenotype resembling that of STAT3-
KO males including excessive apoptosis and impaired angiogenesis.(10) 
Furthermore, our study in Cell(10) describes the PPCM phenotype in 
STAT3-KO mice extensively. There we showed that the physiological 
stresses of pregnancy, labor, and/or nursing resulted in PPCM with a 
high mortality rate in virtually all STAT3-KO female mice studied. Death 
occurred always within the fi rst 3 weeks after delivery. The postpartum 
phenotype of STAT3-KO mice included signs of overt heart failure, 
such as generalized edema and labored breathing, the hearts were 
characterized by four-chamber dilatation, often with thrombi in the 
atria, and extensive fi brosis. Echocardiography analysis revealed left 
ventricular dilatation and depressed fractional shortening in STAT3-KO 
female mice compared with postpartum wildtype sister mice. Molecular 
analysis of left ventricular tissue displayed up-regulation of the hypoxia 
inducible genes (hypoxia inducible factor-1α and BNIP3). Most strikingly, 
we observed a substantial loss of capillaries in ventricles from 
postpartum STAT3-KO females associated with increased cardiac 
apoptosis.
Enhanced cardiac oxidative stress and impaired oxidative 
defence mechanism in postpartum STAT3-KO 
STAT3 is known to protect cardiomyocytes from oxidative stress by the 
up-regulation of the reactive oxygen species (ROS) scavenging enzyme 
manganese superoxide dismutase (MnSOD).(14) The important role of 
MnSOD in oxidative defense has been demonstrated in mice harboring 
only one functional MnSOD gene, where a 50% decrease in levels of 
MnSOD protein is associated with increased oxidative damage and 
cardiomyocyte death.(15) Indeed, the production of superoxide anions 
was enhanced in left ventricles from postpartum STAT3-KO mice 
compared with postpartum wildtype sisters.(10) In contrast, analysis of 
left ventricular tissue from postpartum wildtype female mice showed a 
marked increase in cardiac MnSOD protein levels compared to nulli-
pari females.(10) This increase in MnSOD was blunted in postpartum 
STAT3-KO females. Taken together, this data suggested the presence of 
higher levels of oxidative stress due to an insuffi cient anti-oxidative 
defence system in postpartum STAT3-KO mice (Figure 3).(10)
Is prolactin the heart breaker in postpartum STAT3-KO 
mice?
Prolactin, a dominant hormone in pregnancy and early postpartum, has 
been suggested previously as a potential factor in the pathogenesis of 
PPCM.(16) Interestingly, prolactin can be cleaved by cathepsin D, a 
protease which is activated by oxidative stress in cardiomyocytes(17, 18) 
FIGURE 2:  Baseline plasma infl ammatory markers of deceased patients vs. survivors. 
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 FIGURE 3: Schematic model for the development of PPCM. In absence of cardiomyocyte 
STAT3 activity, oxidative stress (indicated by increased production of reactive oxidant 
species, ROS) is increased, leading to the release of Cathepsin D (CD) from the lysosome 
into the cytoplasm and the interstitium. There it processes 23kDa prolactin (Prl) into its 
detrimental 16kDa form. Subsequently, the 16kDa Prl promotes vasoconstriction, 
apoptosis in endothelial cells, capillary dissociation and interferes with cardiomyocyte 
metabolic activity, all of which subsequently leads to heart failure. Consequently, 
bromocriptine (BR), a pharmacological inhibitor of prolactin release, prevents PPCM in 


















into a 16-kDa form of prolactin, which is known to exert strong anti-
angiogenic effects such as endothelial cell dissociation and apoptosis.(19) 
We were able to demonstrate that left ventricular tissue displays a high 
cleavage activity for prolactin into its 16kDa form.(10) Furthermore, we 
showed that the 16kDa prolactin, even in the absence of the post-
partum physiology, decreased cardiac capillary density and cardiac 
function, thereby mimicking at least in part the cardiac phenotype of 
PPCM in our mouse model (Figure 3).(10)
To obtain further proof of whether or not the generation of the 
16-kDa form of prolactin is involved in the development of PPCM as 
well as to test a potential novel therapeutic strategy, we treated STAT3-
KO female mice for two consecutive pregnancies with bromocriptine, a 
dopamine-D2-receptor agonist, which inhibits prolactin secretion 
(administered 5 days before delivery and continued 3 weeks 
postpartum). Indeed, bromocriptine treatment of STAT3-KO female 
mice prevented the entire PPCM phenotype concerning postpartum 
mortality, cardiac angiogenesis, cardiac function, cardiac dilatation, as well 
as cardiac fi brosis and apoptosis.(10) In Figure 3 we outline schematically 
the pathomechanism of prolactin cleavage and the proposed interference 
of bromocriptine in this pathway by blocking prolactin release from the 
pituitary glands in postpartum STAT3-KO mice.
Increased oxLDL, enhanced activation of Cathepsin D and 
augmented protein levels of the 16-kDa form of prolactin are 
present in the serum of lactating women with PPCM
We analyzed sera collected from PPCM patients and healthy peripartum 
controls for parallels of the pathomechanism of prolactin cleavage 
between our STAT3-mouse model and the human disease of PPCM. 
Indeed, the serum of lactating patients with PPCM contained increased 
levels of oxidized low density lipoprotein (oxLDL), a marker for 
oxidative stress(20) and increased Cathepsin D activity compared to 
healthy lactating women.(10) In addition, we were able to detect an 
antigen corresponding to the 16-kDa prolactin in the sera of 3 out of 5 
lactating PPCM patients with obvious cardiac dysfunction at the time of 
serum sampling (mean %EF: 24±7), while no 16-kDa form of prolactin 
was detectable in healthy lactating women (n=5).(10)
Bromocriptine treatment may prevent PPCM in high-risk 
patients 
PPCM occurs in previously healthy women who cannot be identifi ed 
prospectively. However, women with PPCM who recover normal 
cardiac function have a high risk for reoccurring PPCM.(21) We therefore 
studied 12 patients who had recovered from a previous episode of 
PPCM and presented with a subsequent pregnancy.(10) In these women 
echocardiography was performed before delivery (8 months of 
pregnancy) and 3 months post-delivery. Six of these patients received 
bromocriptine 2.5 bd. after giving birth and subsequently for 2 months 
post-delivery in addition to standard heart failure therapy.(10) Controls 
for this preliminary study consisted of 6 patients with subsequent 
pregnancies after a previous episode of PPCM who presented similar 
pre-delivery cardiac function and dimensions (Table 2) and received 
standard heart failure treatment only.(10) In all patients who received 
additional bromocriptine post-delivery prolactin serum levels were 
returned to non-pregnant levels within 14 days of treatment as 
described previously.(22) Moreover, all bromocriptine treated patients 
presented normalization of LV function and dimensions (Table 2) and 
TABLE 2: Cardiac function and NYHA stage in patients with subsequent 
pregnancies with (n=6) or without (n=6) BR treatment
EF(%) 45±7 40±14 27±5 49±10 23±3 52±6**
NYHA 1.4±0.5 1.8±0.9 3±1 1.5±0.6 2.3±0.6 1±0*
 Peripartum Peripartum Postpartum Postpartum Postpartum Postpartum
 control bromo- control bromo- control bromo-
 predelivery criptine 1 month criptine 3 months criptine 
  predelivery  1 month  3 months
Ejection fraction (EF) was determined by echocardiography peripartum (before bromocriptine (BR) 
treatment was started) and 3 months postpartum. Mean age of control (standard heart failure therapy 
only) group: 32±6 and of BR group (standard heart failure and BR for 8 weeks): 33±4 (n.s). In the control 
group three patients died within 14 weeks postpartum, while all patients in the BR group survived. Data 
are presented as mean±SD, *p<0.05, **p< 0.01 BR group vs. corresponding control group.
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survived the 4-month observation period.(10) In the control group, three 
patients had died and the surviving showed deterioration of LV function 
and marked dilatation of the left ventricle (Table 2).(10)
DISCUSSION AND CONCLUSION                                   
This review summarizes the clinical profi le of 100 PPCM patients at a 
tertiary level hospital in South Africa and examined the role of plasma/
serum pro-infl ammatory markers at the time of diagnosis and clinical 
outcome after 6 months of treatment. In addition, it offers novel insights 
into the pathomechanism of PPCM by comparing a mouse model of 
PPCM with the clinical profi le of human PPCM patients. Finally, it 
suggests that increased myocardial oxidative stress and enhanced 
cathepsin D activity induces a detrimental conversion of prolactin into 
its 16-kDa anti-angiogenic derivative. This 16kDa prolactin may induce 
and drive PPCM in mice and in patients. This highlights a novel specifi c 
treatment strategy for PPCM based on the inhibition of prolactin 
release by the well-established dopamine-D2-receptor agonist 
bromocriptine.
Despite appropriate and optimal clinical care including angeotensin 
converting enzyme (ACE)-inhibitors and carvedilol, 15% of patients 
died and only 23% of the studied population normalized their LVEF 
after 6 months of therapy. Prognosis of patients with PPCM seems to 
vary according to geographical region. Whereas Felker et al.(23) reported 
a 94% survival rate in 52 patients diagnosed at Johns Hopkins Hospital 
in the USA, 14% died in a prospectively studied population in Haiti and 
only 20% regained normal left ventricular function.(24) Poor socio-
economic status, subtle yet undefi ned nutritional defi ciencies, genetic 
factors and inadequate pre- and postnatal care could contribute to 
these geographical differences. The only options for patients who do 
not regain normal left ventricular function are the use of left ventricular 
assist devices and cardiac transplantation. However, such options are 
not available in resource-poor settings, such as in Haiti and South Africa. 
Patients that died had lower NYHA FC, LVEF and larger left ventricular 
dimensions at diagnosis compared to those who survived, whereas age, 
parity or onset of symptoms did not appear to play a role. Demakis et 
al. found that pathological fi ndings in the myocardium of patients whose 
hearts had returned to normal size within six months of treatment and 
those whose hearts had not returned to normal size were 
indistinguishable.(25)
CRP is an acute-phase protein which recognizes a range of pathogenic 
targets, including membranes of apoptotic and reactive cells.(26) As this 
infl ammatory marker is associated with adverse prognosis in patients 
with idiopathic dilated cardiomyopathy,(27, 28) we investigated if levels of 
plasma CRP at baseline could predict outcome in patients with PPCM. 
Almost half of the population investigated had raised levels of CRP 
refl ecting possibly the presence of a low-grade chronic infl ammatory 
process due to the release of endotoxin or endotoxin-like substances 
and subsequent release of pro-infl ammatory cytokines.(29) However, we 
did not fi nd a correlation with NYHA FC or death. None of the patients 
with PPCM presented with symptoms during the antepartum period. 
This is in contrast to studies performed by others(30) and more in 
keeping with a study from Haiti(24) documenting that 96% of patients 
with PPCM developed heart failure in the postpartum period. Our 
failure to include PPCM patients during the prepartum period in the 
present study was not due to a lack of identifying such patients, since 
the cardiologists at Chris Hani Baragwanath Hospital are routinely 
involved in the care of pregnant patients presenting with symptoms and 
signs of congestive cardiac failure.  The majority of cases developed 
symptoms in the fi rst 4 weeks postpartum. Twenty per cent of patients 
studied were primiparous. We could not confi rm factors mentioned by 
others(30) as multiparity, older age, or long-term use of tocolytic agents 
to be associated with the development of PPCM. At presentation, this 
group of patients had acute onset heart failure of short duration. There 
was no evidence of chronic disease or cardiac cachexia that could 
account for a low lipid profi le being a marker of severe, chronic disease. 
Mean plasma levels of total cholesterol of the patient population 
studied was 4.2±0.8 mmol/L and low compared to that reported in 
other studies.(31-33) In a study by Rauchhaus and colleagues with an 
established plasma cholesterol cut-off level of < 5.2 mmol/L, low total 
cholesterol level was found to be predictive for impaired 1-year 
survival.(32) In line with fi ndings by others(31, 32) demonstrating an increase 
in the rate of mortality with low serum total cholesterol levels, we 
found an association of low total cholesterol levels with larger left 
ventricular dimensions and lower EF. There was a trend, but no 
statistically signifi cant association between the rate of mortality, which 
could possibly be explained by the short duration of the trial, the limited 
number of patients studied and the spontaneous recovery rate typical 
for patients with PPCM. Levels of low plasma cholesterol correlated 
positively with the levels of the infl ammatory marker CRP. These 
fi ndings are in support of the endotoxin-lipoprotein hypothesis(29) 
suggesting that lower plasma levels of total cholesterol provide lesser 
protection against endotoxins, making a susceptible group of patients 
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colleagues(34) showed a signifi cant variation in the distribution of plasma 
CRP levels among various ethnic groups living in the United States. 
Median plasma CRP levels were signifi cantly higher among black women 
compared to their white, Hispanic or Asian counterparts. Since 40% of 
the variance of plasma CRP levels is genetically determined and PPCM 
is much more frequent in black patients, one could hypothesize that an 
increase in the intensity of an infl ammatory response could be one of 
many factors contributing towards the development of PPCM. This is 
supported by our previous research in PPCM patients presenting with 
subsequent pregnancy, where we observed an exaggerated postpartum 
pro-infl ammatory cytokine surge possibly playing a role in the 
development of PPCM.(21) Plasma levels of Fas/Apo-1 in the PPCM 
patients were signifi cantly higher compared to healthy controls and a 
predictor of mortality, indicating that cardiac apoptosis may play a causal 
role in the pathogenesis of PPCM. Indeed, our mouse model of PPCM 
emphasizes increased cardiac apoptosis associated with the PPCM 
phenotype. However, most patients with acute PPCM have normal or 
only slightly increased troponin T or creatinine kinase (CK) serum levels, 
indicating that apoptosis may not affect primarily cardiomyocytes, but 
rather non-myocyte cells such as cardiac endothelial cells as suggested 
by our mouse model of PPCM.(10) In this regard, our experimental 
fi ndings suggest a novel pathomechanism of heart failure, where a 
cleaved form of the pregnancy and nursing hormone prolactin, 16kDa 
prolactin, targets the endothelium, leading to impairment of the cardiac 
microcirculation and possibly thereby inducing and/or promoting 
progression of PPCM.(10) Our fi ndings of increased cathepsin D activity 
and the presence of the 16-kDa form of prolactin in serum samples of 
nursing PPCM patients but not in pregnancy-matched controls,(10) point 
to striking similarities between our experimental mouse model of 
PPCM and support the concept of this pathomechanism in PPCM 
patients.
Clinical studies have determined that bromocriptine is safe during 
pregnancy.(35) Our encouraging preliminary results in patients treated 
with a combination of bromocriptine and standard heart-failure therapy 
compared to patients treated with standard heart-failure therapy only 
could further support the hypothesis that the 16-kDa form of prolactin 
may represent a causal factor for development of PPCM in patients.(10)
In conclusion, the well characterized profi le of 100 PPCM patients, in 
combination with basic science, enables a unique concept of translational 
research, which provides new insights into the pathomechanisms behind 
heart failure and, more specifi cally, PPCM. In addition, this concept may 
have contributed to a novel and more specifi c therapeutic option to 
treat patients with PPCM or prevent the disease in patients who 
suffered and recovered from PPCM in a previous pregnancy. However, 
additional data, mainly a controlled randomized study, is needed in 
order to determine the true value of bromocriptine as a specifi c novel 
therapy for PPCM.
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